[
  {
    "ts": "2026-01-10T02:09:51+00:00",
    "headline": "Is It Time To Reassess Amgen (AMGN) After Its 28% One Year Share Price Gain?",
    "summary": "If you are wondering whether Amgen's current share price still offers value after a strong run, this article walks through what the numbers are really saying about the stock. Over the last year Amgen has returned 28.4%, with a 3.4% gain over the past 30 days, while the year-to-date return and 7-day move both sit at 0.5% declines, which may have shifted how some investors think about its potential and risk. Recent headlines around Amgen have focused on its position as a large biotech player,...",
    "url": "https://finance.yahoo.com/news/time-reassess-amgen-amgn-28-020951356.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "5951073c-ef44-365f-a74e-e387bb6d0d85",
      "content": {
        "id": "5951073c-ef44-365f-a74e-e387bb6d0d85",
        "contentType": "STORY",
        "title": "Is It Time To Reassess Amgen (AMGN) After Its 28% One Year Share Price Gain?",
        "description": "",
        "summary": "If you are wondering whether Amgen's current share price still offers value after a strong run, this article walks through what the numbers are really saying about the stock. Over the last year Amgen has returned 28.4%, with a 3.4% gain over the past 30 days, while the year-to-date return and 7-day move both sit at 0.5% declines, which may have shifted how some investors think about its potential and risk. Recent headlines around Amgen have focused on its position as a large biotech player,...",
        "pubDate": "2026-01-10T02:09:51Z",
        "displayTime": "2026-01-10T02:09:51Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/8ab44b8ef28c7f69299492d5b9c5a46c",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ACuIXYrNeojUXbAJFhnPIg--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/8ab44b8ef28c7f69299492d5b9c5a46c.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/B7CQJIEa.2c0sQ0XIU66pg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/8ab44b8ef28c7f69299492d5b9c5a46c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/time-reassess-amgen-amgn-28-020951356.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/time-reassess-amgen-amgn-28-020951356.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AMGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]